Background
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with poor median survival (9–11 months).
- Immune checkpoint blockade (ICB) + chemotherapy has only modestly improved outcomes.
- SCLC evades immunity by suppressing MHC-I and antigen presentation.
- The mechanism of HLA repression and therapeutic strategies remains poorly understood.
- We analyzed clinical SCLC and NE tumor samples to: (1) Define molecular subtypes; (2) Identify key regulators of MHC repression.